Atrandi Biosciences 🇱🇹

Series A

Semi-permeable capsule technology for high-throughput single-cell multi-omics and genomics. Vilnius.

About Atrandi Biosciences

Atrandi Biosciences specializes in single-cell analysis through its patented Semi-Permeable Capsule (SPC) technology, which allows for the isolation of tens of thousands of single cells in permeable compartments, facilitating bulk reactions while maintaining single-cell resolution. This technology enables advanced multi-omic workflows, high-throughput microbial and eukaryotic genomics, and the ability to run complex assays without compromising data quality.

Atrandi Biosciences is a Lithuania-based company founded in 2016, now around 80 people.

Founded by Juozas Nainys (CEO & co-founder; previously VU Fizikos fakultetas; Vilnius University), Linas Mažutis (Co-founder and founding CEO; repeat founder; previously PlateletBio; Université de Strasbourg).

Its investors also appear on FundFinder's most-active lists for Series A · AI (62 funds), Series A · DeepTech (53 funds), Series A · Life Sciences (20 funds).

Company facts from Harmonic and public filings; team backgrounds from public profiles. Refreshed weekly.

Want the latest on Atrandi Biosciences? Our research agent pulls the current description, latest round and full investor base from public sources (about a minute).

Series A · Feb 2025

InvestorsLCLux Capital

Lux Capital — New York-based deep-tech VC investing from seed to growth at the intersection of science, technology and national security: AI, advanced manufacturing, energy, biotech and defence. · cheques £1M – £20M

Raising your own round? See which European funds fit →